Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-A Phase 3 study of vutrisiran versus patisiran in hereditary transthyretin amyloidosis
jRCT2080224769Phase 3Completed
- Sponsor
- CMIC Group
- Start
- Jul 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, open-label trial of vutrisiran in hereditary transthyretin amyloidosis (hATTR) (2 arms), sponsored by CMIC Group. Started Jul 2019; status: completed.
02
Drugs
vutrisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on jRCT2080224769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224769.